NZ333621A - Cationic polymer and lipoprotein-containing system for gene delivery - Google Patents

Cationic polymer and lipoprotein-containing system for gene delivery

Info

Publication number
NZ333621A
NZ333621A NZ333621A NZ33362197A NZ333621A NZ 333621 A NZ333621 A NZ 333621A NZ 333621 A NZ333621 A NZ 333621A NZ 33362197 A NZ33362197 A NZ 33362197A NZ 333621 A NZ333621 A NZ 333621A
Authority
NZ
New Zealand
Prior art keywords
composition
lipoprotein
nucleic acid
weight
stearyl
Prior art date
Application number
NZ333621A
Other languages
English (en)
Inventor
Jin-Seok Kim
Atsushi Maruyama
Toshihiro Akaike
Sung Wan Kim
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of NZ333621A publication Critical patent/NZ333621A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NZ333621A 1996-07-03 1997-07-03 Cationic polymer and lipoprotein-containing system for gene delivery NZ333621A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/675,120 US5679559A (en) 1996-07-03 1996-07-03 Cationic polymer and lipoprotein-containing system for gene delivery
PCT/US1997/012425 WO1998000556A1 (en) 1996-07-03 1997-07-03 Cationic polymer and lipoprotein-containing system for gene delivery

Publications (1)

Publication Number Publication Date
NZ333621A true NZ333621A (en) 1999-09-29

Family

ID=24709138

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333621A NZ333621A (en) 1996-07-03 1997-07-03 Cationic polymer and lipoprotein-containing system for gene delivery

Country Status (8)

Country Link
US (1) US5679559A (enExample)
EP (1) EP0958369A4 (enExample)
JP (1) JP2001501812A (enExample)
KR (1) KR100536979B1 (enExample)
AU (1) AU717109B2 (enExample)
CA (1) CA2259139A1 (enExample)
NZ (1) NZ333621A (enExample)
WO (1) WO1998000556A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264012C (en) * 1996-08-13 2011-04-26 Chiron Corporation Compositions and methods for polynucleotide delivery
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
AU8692598A (en) 1997-08-04 1999-02-22 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US5973119A (en) * 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
US6344541B1 (en) * 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
DK1149114T3 (da) 1999-02-03 2014-06-23 Amgen Inc Polypeptider, der er involveret ved et immunrespons
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
AU3770800A (en) 1999-03-26 2000-10-16 Amgen, Inc. Beta secretase genes and polypeptides
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
EP1209971A4 (en) * 1999-08-20 2004-04-14 Mirus Corp POLYION COMPLEX LOAD INVERSION
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US6900043B1 (en) * 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
US20050239061A1 (en) * 2000-03-01 2005-10-27 Marshall William S Identification and use of effectors and allosteric molecules for the alteration of gene expression
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
WO2002000710A2 (en) * 2000-06-28 2002-01-03 Amgen, Inc. B7-like molecules and uses thereof
JP2004519205A (ja) 2000-06-28 2004-07-02 アムジェン インコーポレイテッド 胸腺間質リンホポイエチンレセプター分子およびその使用
WO2002044364A2 (en) 2000-11-28 2002-06-06 Amgen Inc. Polypeptides involved in immune response
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
AU2003217693A1 (en) * 2002-02-22 2003-09-09 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
WO2003078576A2 (en) * 2002-03-12 2003-09-25 Nitto Denko Corporation Vector for transfection of eukaryotic cells
GB0212826D0 (en) * 2002-05-31 2002-07-10 Dna Res Innovations Ltd Materials and methods relating to polyions and substance delivery
PL378879A1 (pl) * 2002-12-30 2006-05-29 Amgen Inc. Terapia skojarzona z czynnikami kostymulującymi
EP1773998A2 (en) * 2004-04-20 2007-04-18 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20060035815A1 (en) * 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
WO2006009575A1 (en) 2004-06-22 2006-01-26 The Board Of Trustees Of The University Of Illinois METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
JP2009507852A (ja) * 2005-09-08 2009-02-26 エムディーアールエヌエー，インコーポレイテッド リボ核酸の細胞への送達用医薬組成物
US20100129460A1 (en) * 2005-10-14 2010-05-27 Nastech Pharmaceutical Company Inc. Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeutics
US20070281900A1 (en) * 2006-05-05 2007-12-06 Nastech Pharmaceutical Company Inc. COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
US20070269892A1 (en) * 2006-05-18 2007-11-22 Nastech Pharmaceutical Company Inc. FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
US20070275923A1 (en) * 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
US8282918B2 (en) * 2007-07-30 2012-10-09 University Of Iowa Research Foundation Polynucleotides encoding RPA4/RPA32 hybrid polypeptides
WO2009051451A2 (en) * 2007-10-17 2009-04-23 Korea Advanced Institute Of Science And Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EA201990619A1 (ru) 2008-10-10 2019-07-31 Амген Инк. Fgf21 мутанты и их применение
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
SG10201402038WA (en) 2009-05-05 2014-07-30 Amgen Inc FGF21 Mutants And Uses Thereof
AU2010262927A1 (en) * 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
TWI373338B (en) * 2009-08-27 2012-10-01 Nat Univ Chung Cheng Pharmaceutical composition containing transcription factor decoys and their preparation method and applications
EP2497830A1 (en) 2009-11-05 2012-09-12 Proyecto de Biomedicina Cima, S.L. Regulated expression systems
JP2013512672A (ja) * 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
US9273316B2 (en) 2010-05-21 2016-03-01 Peptimed, Inc. Reagents and methods for treating cancer
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
US10005936B2 (en) * 2012-11-23 2018-06-26 Nanyang Technological University Photoactive bioadhesive compositions
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US12226529B2 (en) 2015-08-25 2025-02-18 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US12083223B2 (en) * 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
AR120309A1 (es) 2019-10-28 2022-02-09 Medimmune Ltd Formulaciones de polvo seco de anticuerpos que se unen a la linfopoyetina del estroma tímico (tslp) y métodos de uso de las mismas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings

Also Published As

Publication number Publication date
KR20000023602A (ko) 2000-04-25
KR100536979B1 (ko) 2005-12-14
US5679559A (en) 1997-10-21
CA2259139A1 (en) 1998-01-08
JP2001501812A (ja) 2001-02-13
EP0958369A4 (en) 2004-11-17
AU717109B2 (en) 2000-03-16
WO1998000556A1 (en) 1998-01-08
EP0958369A1 (en) 1999-11-24
AU3802397A (en) 1998-01-21

Similar Documents

Publication Publication Date Title
AU717109B2 (en) Cationic polymer and lipoprotein-containing system for gene delivery
Jeong et al. Poly (L-lysine)-g-poly (D, L-lactic-co-glycolic acid) micelles for low cytotoxic biodegradable gene delivery carriers
Nimesh et al. RETRACTED: Polyethylenimine nanoparticles as efficient transfecting agents for mammalian cells
RU2440380C2 (ru) Биодеградируемые катионные полимеры
Dutta et al. RETRACTED: Dendrimer nanocarriers as versatile vectors in gene delivery
AU2007238965B2 (en) Biodegradable cationic polymers
US7772201B2 (en) Highly branched HK peptides as effective carriers of siRNA
Debus et al. Delivery of messenger RNA using poly (ethylene imine)–poly (ethylene glycol)-copolymer blends for polyplex formation: Biophysical characterization and in vitro transfection properties
ES2453317T3 (es) Poliaminoácido catiónico de cadena corta y uso del mismo
US8658150B2 (en) Polymer derived from linear polyethylenimine for gene transfer
JP2007521247A (ja) 生体適合性−遺伝子送達剤としての新規カチオン性リポポリマー
US8546487B2 (en) Cationic poly (amino acids) and uses thereof
WO2004087931A1 (en) Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof
Leiro et al. Biodegradable PEG–dendritic block copolymers: synthesis and biofunctionality assessment as vectors of siRNA
Nimesh et al. Guanidinium-grafted polyethylenimine: an efficient transfecting agent for mammalian cells
EP1115428B1 (en) Cationic dendrimeric compounds and their use as oligonucleotide/polynucleotide carriers
Gabrielson et al. Multiplexed supramolecular self-assembly for non-viral gene delivery
US7163677B2 (en) Cationic polymers having degradable crosslinks
US20100093094A1 (en) Triazine dendrimers and methods of making and using the same for nucleic acid transport
KR100466254B1 (ko) 세포내 전달을 위한 올리고뉴클레오티드와 친수성 고분자로 구성되는 유전자 전달용 접합체, 고분자 전해질 복합 미셀 및 그의 제조방법
Bhattacharya et al. Targeted Delivery of Complexes of Biotin–PEG–Polyethylenimine and NF-κB Decoys to Brain-derived Endothelial Cells in Vitro
Restiani et al. Optimization transgene expression of short fully synthesized lipopeptide-based transfection agent for non-viral gene delivery vehicle
Arote et al. Folate conjugated poly (ester amine) for lung cancer therapy
Ramirez Improving Gene Delivery Efficiency by Lipid Modification of Cationic Polymers
Incani Ramirez Improving gene delivery efficiency by lipid modification of cationic polymers

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)